Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 10 Jun 2021
Integrating early economic evaluation into target product profile development for medical tests: advantages and potential applications
7 June 2021 - Target product profiles outline the characteristics that new health care technologies require to address an unmet clinical ...
Posted by Michael Wonder on 09 Jun 2021
Stop blaming PHARMAC - we'd be worse off without it
10 June 2021 - Penny Tucker is concerned that there are “miracle drugs and biologics that have transformed many conditions ...
Posted by Michael Wonder on 09 Jun 2021
Paladin Labs announces approval of Wakix (pitolisant) in Canada
9 June 2021 - Paladin Labs today announced Health Canada's approval of Wakix (pitolisant) for the treatment of excessive daytime sleepiness ...
Posted by Michael Wonder on 09 Jun 2021
End ‘vaccine frustration’ and let pharmacies join the rollout: Pharmacy Guild
9 June 2021 - New South Wales, Victoria and Western Australia could all soon join Queensland in allowing rural or ...
Posted by Michael Wonder on 09 Jun 2021
New Alzheimer’s drug unlikely to be approved in Australia soon, say experts
9 June 2021 - A controversial new drug that has offered hope to Alzheimer’s sufferers by slowing cognitive decline still ...
Posted by Michael Wonder on 09 Jun 2021
Australia tipped to approve Pfizer vaccine for children this year
9 June 2021 - Infectious diseases paediatricians and vaccine experts anticipate the Pfizer shot could be approved for use in ...
Posted by Michael Wonder on 09 Jun 2021
Pharma funded more than 2,400 state law maker campaigns in 2020, new STAT analysis finds
9 June 2021 - State lawmakers in Oregon have tried to lower high drug prices from nearly every angle: they’ve sought ...
Posted by Michael Wonder on 09 Jun 2021
Vertex announces U.S. FDA approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 through 11 with certain mutations
9 June 2021 - With this approval approximately 1,500 children with one minimal function mutation and one F508del mutation have a ...
Posted by Michael Wonder on 09 Jun 2021
Ibex granted FDA breakthrough device designation
9 June 2021 - Ibex's Galen AI powered platform is recognised by the FDA as breakthrough technology with the potential to ...
Posted by Michael Wonder on 09 Jun 2021
BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in microsatellite instability-high or mismatch repair-deficient solid tumours
7 June 2021 -BeiGene today announced that the Center for Drug Evaluation of the China NMPA has accepted a supplemental ...
Posted by Michael Wonder on 09 Jun 2021
Prescription drug price increases continue to outpace inflation
7 June 2021 - New AARP report shows even during pandemic consumers have had to pay more for medicines. ...
Posted by Michael Wonder on 09 Jun 2021
Alzheimer’s drug is bonanza for Biogen, most likely at taxpayer expense
8 June 2021 - The FDA’s decision on Monday to approve a new Alzheimer’s medication over the fierce objections of ...
Posted by Michael Wonder on 09 Jun 2021
Millions of J&J COVID-19 vaccines are at risk of expiring in June
8 June 2021 - States, hospitals try to reroute such vaccines, while efforts to export them face hurdles. ...
Posted by Michael Wonder on 09 Jun 2021
AMA and Australian Government agree to strengthening the MBS review process and informed financial consent
8 June 2021 - The Australian Government and the Australian Medical Association have reached agreement to work together to co-design the ...
Posted by Michael Wonder on 09 Jun 2021
Amicus Therapeutics announces United Kingdom’s MHRA grants early access to AT-GAA
8 June 2021 - Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the ...